-2.87%
-13.62%
28.48%
-56.25%
-43.77%
-66.61%
-76.45%
AI Spotlight on FULC
Company Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases.
Fulcrum Therapeutics, Inc.has research and discovery collaboration agreement with Acceleron Pharma Inc.to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc.
to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies.Fulcrum Therapeutics, Inc.was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Market Data
| Last Price | 4.06 |
| Change Percentage | -2.87% |
| Open | 4.18 |
| Previous Close | 4.18 |
| Market Cap ( Millions) | 219 |
| Volume | 159193 |
| Year High | 13.7 |
| Year Low | 2.86 |
| M A 50 | 4.06 |
| M A 200 | 5.94 |
Financial Ratios
| FCF Yield | -3.99% |
| Dividend Yield | 0.00% |
| ROE | -7.31% |
| Debt / Equity | 3.55% |
| Net Debt / EBIDTA | 267.60% |
| Price To Book | 0.98 |
| Price Earnings Ratio | -14.15 |
| Price To FCF | -25.06 |
| Price To sales | 2.71 |
| EV / EBITDA | -6.55 |
News
- Nov -28 - Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why
- Nov -26 - Fulcrum Therapeutics to Participate in Upcoming December Conferences
- Nov -14 - Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript
- Nov -12 - Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
- Nov -12 - New Strong Buy Stocks for November 12th
- Nov -06 - Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
- Oct -25 - Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?
- Oct -15 - Fulcrum Therapeutics, Inc. Being Investigated on Behalf of Fulcrum Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details
- Oct -14 - Fulcrum Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - FULC
- Oct -11 - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Oct -11 - Levi & Korsinsky Announces an Investigation on Behalf of Fulcrum Therapeutics, Inc. (FULC) Shareholders Who May Have Been Affected by Fraud
- Oct -10 - Investors who lost money on Fulcrum Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - FULC
- Oct -09 - Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
- Oct -09 - Levi & Korsinsky Announces an Investigation on Behalf of Fulcrum Therapeutics, Inc. (FULC) Shareholders Who May Have Been Affected by Fraud
- Oct -08 - An Investigation Has Commenced on Behalf of Fulcrum Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your FULC Losses
- Oct -07 - FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares
- Oct -07 - Shareholder Rights Advocates at Levi & Korsinsky Investigate Fulcrum Therapeutics, Inc. (FULC) Regarding Possible Securities Fraud Violations
- Oct -04 - Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround
- Oct -02 - Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud
- Oct -01 - Fulcrum Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights β FULC
Business Breakdown
Expected Mid-Term Growth
Segment nΒ°1 -> Biopharmaceutical
Expected Growth : 10.43 %
What the company do ?
Fulcrum Therapeutics' biopharmaceuticals focus on developing small molecule therapies to modulate gene expression for rare genetic diseases.
Why we expect these perspectives ?
Fulcrum Therapeutics' 10.43% growth in biopharmaceuticals is driven by increasing demand for rare genetic disorder treatments, strategic partnerships, and a strong pipeline of novel therapies. The company's focus on gene regulation and epigenetics is also contributing to its growth, as well as its ability to leverage AI and machine learning in drug discovery.
Fulcrum Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| Fulcrum's FTX-6058 | FTX-6058 is a small molecule designed to increase the expression of FUS, a protein that is deficient in individuals with FSHD. |
| Fulcrum's Losmapimod | Losmapimod is a p38Ξ±/Ξ² inhibitor that has been shown to reduce inflammation and improve muscle function in patients with FSHD. |
| Fulcrum's FTX-020 | FTX-020 is a small molecule designed to increase the expression of a key protein involved in the regulation of muscle function. |
| Fulcrum's Gene Therapy Programs | Fulcrum's gene therapy programs are designed to treat genetic disorders by delivering a healthy copy of a gene to cells. |
Fulcrum Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
Fulcrum Therapeutics, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
Bargaining Power Of Customers
Fulcrum Therapeutics, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.
Bargaining Power Of Suppliers
Fulcrum Therapeutics, Inc. relies on a few key suppliers for raw materials and services. While the company has some bargaining power due to its size, the suppliers also have some leverage due to the specialized nature of their products.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant capital requirements, complex regulatory requirements, and the need for specialized expertise. These barriers make it difficult for new entrants to enter the market.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. Fulcrum Therapeutics, Inc. faces intense competition from companies with similar products and technologies.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 4.40% |
| Debt Cost | 3.95% |
| Equity Weight | 95.60% |
| Equity Cost | 15.68% |
| WACC | 15.16% |
| Leverage | 4.60% |
Fulcrum Therapeutics, Inc. : Quality Control
Fulcrum Therapeutics, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| LPCN | Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral β¦ |
| CLSD | Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone β¦ |
| EYPT | EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, β¦ |
| RIGL | Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase β¦ |
| ASMB | Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate β¦ |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
π₯
Lipocine
A-Score
1-Year Total Return ->
π₯
Rigel Pharma
A-Score
1-Year Total Return ->
π₯
Assembly Biosciences
A-Score
1-Year Total Return ->
4
Clearside Biomedical
A-Score
1-Year Total Return ->
5
EyePoint Pharmaceuticals
A-Score
1-Year Total Return ->
6
